Articles

Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.

The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.

First a little explanation about the new unique product with its own delivery system. This is not only a medication but also a matchstick-sized osmotic mini pump that is the size of a match and is placed just beneath the skin to deliver a continuous and consistent flow of medication for a year.

Does liraglutide help in the reduction of cardiovascular diseases?

Is semaglutide a better way to manage type 2 diabetes?

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.

Exercise shown to have some AFib-specific benefits.

Harvard researchers find as many as 40 percent of cancer cases, and half of cancer deaths, come down to things people could easily change.